NADMED Story
The story of NADMED began in 2014 at Anu Wartiovaara Suomalainen’s mitochondrial research laboratory at the University of Helsinki. The team was studying mitochondrial myopathy, a rare condition that weakens muscle function and can lead to severe paralysis. During their investigations, they discovered that NAD molecules played a central role in the disease.
But moving from mouse studies to human research posed a challenge: how could NADs be measured safely and reliably in people? Muscle biopsies were far too invasive, and existing techniques required mass spectrometry, which came with significant limitations.
VIDEO: Michelle Livings visits NADMED.
Nadmed Mission: NADMED offers advanced tools, data, and expertise to measure and interpret information about an individual’s metabolic health, especially NADs, glutathiones, and related molecules, for the benefit of patients and the global medical community. Our products and services improve diagnostics and treatment results for an increasing number of age-related and metabolic medical conditions. Researchers and the pharmaceutical industry use them to advance science and develop new therapies and personalized medicine.
Nadmed Vision: Measuring the four NADs and glutathiones will become a routine medical test, serving as an actionable tool for patients with degenerative and metabolic diseases, and providing a readout of the effectiveness of metabolic therapies. As markers of metabolic health, these six metabolites will also become a standard test for personalized, preventive medicine. NADMED will be the leading innovator and expert in the analysis of key metabolic regulators, developing and providing efficient, high-precision technology.
After an extensive review of the scientific literature, one of the team members, Dr. Liliya Euro, took on the challenge of developing a laboratory method that could accurately measure NADs in a simpler way. Step by step -first in plants, then in mice, and eventually in humans -she created a robust and reliable assay for measuring NADs from blood.
The method was so effective that research groups around the world immediately began requesting it. This growing demand sparked the idea of bringing the technology beyond the walls of the university.
And so, in 2022, NADMED was founded, turning a scientific breakthrough into a global tool for advancing metabolic and redox research.
Get to know us!






Riikka Äänismaa
Head of Medical and Regulatory Affairs


Konstantin Kogan
Senior R&D Scientist,





Board of Directors

Anu Suomalainen Wartiovaara
Board chairperson
Co-Founder, MD, PhD

Juha Tuominen
Board member
MD, PhD

Ilkka Salonen
Board member
MSc

Sebastian Soidinsalo
Board member
MSc, MBA.Bio
Scientific Advisory Board

Prof. Charles Brenner
PhD

Prof. Rita Horvath
MD, PhD

Dr. Helen Messier
MD, PhD
